Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
pneumococcal disease
Pharma
Merck's new Capvaxive scores key CDC vaccine panel endorsement
The recommendation sets up Merck's new pneumococcal disease vaccine to potentially capture some of Pfizer's market share.
Zoey Becker
Jun 28, 2024 11:44am
Merck's Prevnar rival snags key pediatric nod
Jun 22, 2022 6:45am
Merck's Vaxneuvance makes its case for FDA approval in children
Oct 4, 2021 10:08am
Merck moves a step closer in advancement of its next-gen shot
Aug 25, 2021 9:13am
Merck pads case for next-gen pneumococcal shot in kids
May 20, 2021 8:28am
Merck, Pfizer pneumonia vaccines running low in EU
Oct 23, 2020 10:45am
